Telomerase: a good target in hepatocellular carcinoma? An overview of relevant preclinical data

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 May;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019 Jan;156(2):477–491.e1.
   PubMed Web of Science ®Google Scholar
• McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021 Jan;73(Suppl 1):4–13.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021 Jan 21;7(1):6.
   PubMed Web of Science ®Google Scholar
• EASL Clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018 Jul;69(1):182–236.
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391(10126):1163–1173.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 Jul 24;359(4):378–390.
   PubMed Web of Science ®Google Scholar
• Kelley RK, Mollon P, Blanc JF, et al. Comparative efficacy of cabozantinib and regorafenib for advanced hepatocellular carcinoma. Adv Ther. 2020 Jun;37(6):2678–2695.
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020 May 14;382(20):1894–1905.
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017 Jun 24;389(10088):2492–2502.
   PubMed Web of Science ®Google Scholar
• Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Jan 7;389(10064):56–66.
   PubMed Web of Science ®Google Scholar
• Wang H, Chen X, Calvisi DF. Hepatocellular carcinoma (HCC): the most promising therapeutic targets in the preclinical arena based on tumor biology characteristics. Expert Opin Ther Targets. 2021 Aug;25(8):645–658.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Electronic address wbe, cancer genome atlas research N. comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell. 2017 Jun 15;169(7):1327–1341 e23.
   PubMed Web of Science ®Google Scholar
• Paterlini-Brechot P, Saigo K, Murakami Y, et al. Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene. 2003 Jun 19;22(25):3911–3916.
   PubMed Web of Science ®Google Scholar
• Sung WK, Zheng H, Li S, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet. 2012 May 27;44(7):765–769.
   PubMed Web of Science ®Google Scholar
• Nault JC, Datta S, Imbeaud S, et al. Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet. 2015 Oct;47(10):1187–1193.
   PubMed Web of Science ®Google Scholar
• La Bella T, Imbeaud S, Peneau C, et al. Adeno-associated virus in the liver: natural history and consequences in tumour development. Gut. 2020 Apr;69(4):737–747.
   PubMed Web of Science ®Google Scholar
• Tornesello ML, Buonaguro L, Tatangelo F, et al. Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections. Genomics. 2013 Aug;102(2):74–83.
   PubMed Web of Science ®Google Scholar
• Sia D, Jiao Y, Martinez-Quetglas I, et al. Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features. Gastroenterology. 2017 Sep;153(3):812–826.
   PubMed Web of Science ®Google Scholar
• Pinyol R, Sia D, Llovet JM. Immune exclusion-Wnt/CTNNB1 class predicts resistance to immunotherapies in HCC. Clin Cancer Res. 2019 Apr 1;25(7):2021–2023.
   PubMed Web of Science ®Google Scholar
• Nault JC, Ningarhari M, Rebouissou S, et al. The role of telomeres and telomerase in cirrhosis and liver cancer. Nat Rev Gastroenterol Hepatol. 2019 Sep;16(9):544–558.
   PubMed Web of Science ®Google Scholar
• Lin S, Nascimento EM, Gajera CR, et al. Distributed hepatocytes expressing telomerase repopulate the liver in homeostasis and injury. Nature. 2018 Apr;556(7700):244–248.
   PubMed Web of Science ®Google Scholar
• der Stroth L, Tharehalli U, Gunes C, et al. Telomeres and telomerase in the development of liver cancer. Cancers (Basel). 2020 Jul 24;12(8):2048 .
   PubMed Web of Science ®Google Scholar
• Kitada T, Seki S, Kawakita N, et al. Telomere shortening in chronic liver diseases. Biochem Biophys Res Commun. 1995 Jun 6;211(1):33–39.
   PubMed Web of Science ®Google Scholar
• Jang JW, Kim JS, Kim HS, et al. Significance of TERT genetic alterations and telomere length in hepatocellular carcinoma. Cancers (Basel). 2021 Apr 30;13(9):2160.
   PubMed Web of Science ®Google Scholar
• Horn S, Figl A, Rachakonda PS, et al. TERT promoter mutations in familial and sporadic melanoma. Science. 2013 Feb 22;339(6122):959–961.
   PubMed Web of Science ®Google Scholar
• Huang FW, Hodis E, Xu MJ, et al. Highly recurrent TERT promoter mutations in human melanoma. Science. 2013 Feb 22;339(6122):957–959.
   PubMed Web of Science ®Google Scholar
• Killela PJ, Reitman ZJ, Jiao Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6021–6026.
   PubMed Web of Science ®Google Scholar
• Nault JC, Mallet M, Pilati C, et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun. 2013;4:2218.
   PubMed Web of Science ®Google Scholar
• Totoki Y, Tatsuno K, Covington KR, et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet. 2014 Dec;46(12):1267–1273.
   PubMed Web of Science ®Google Scholar
• Schulze K, Imbeaud S, Letouze E, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015 May;47(5):505–511.
   PubMed Web of Science ®Google Scholar
• Pezzuto F, Buonaguro L, Buonaguro FM, et al. Frequency and geographic distribution of TERT promoter mutations in primary hepatocellular carcinoma. Infect Agent Cancer. 2017;12:27.
   PubMed Web of Science ®Google Scholar
• Nault JC, Calderaro J, Di Tommaso L, et al. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology. 2014 Dec;60(6):1983–1992.
   PubMed Web of Science ®Google Scholar
• Hiyama E, Hiyama K. Telomere and telomerase in stem cells. Br J Cancer. 2007 Apr 10;96(7):1020–1024.
   PubMed Web of Science ®Google Scholar
• Smith EM, Pendlebury DF, Nandakumar J. Structural biology of telomeres and telomerase. Cell Mol Life Sci. 2020 Jan;77(1):61–79.
   PubMed Web of Science ®Google Scholar
• Cristofari G, Lingner J. Telomere length homeostasis requires that telomerase levels are limiting. EMBO J. 2006 Feb 8;25(3):565–574.
   PubMed Web of Science ®Google Scholar
• Jafri MA, Ansari SA, Alqahtani MH, et al. Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies. Genome Med. 2016 Jun 20;8(1):69.
   PubMedGoogle Scholar
• Baur JA, Zou Y, Shay JW, et al. Telomere position effect in human cells. Science. 2001 Jun 15;292(5524):2075–2077.
   PubMed Web of Science ®Google Scholar
• Kim W, Ludlow AT, Min J, et al. Regulation of the Human Telomerase Gene TERT by Telomere Position Effect-Over Long Distances (TPE-OLD): implications for aging and cancer. PLoS Biol. 2016 Dec;14(12):e2000016.
   PubMed Web of Science ®Google Scholar
• Shay JW, Wright WE. Hayflick, his limit, and cellular ageing. Nat Rev Mol Cell Biol. 2000 Oct;1(1):72–76.
   PubMed Web of Science ®Google Scholar
• Kawanishi S, Oikawa S. Mechanism of telomere shortening by oxidative stress. Ann N Y Acad Sci. 2004 Jun;1019:278–284.
   PubMed Web of Science ®Google Scholar
• Jurk D, Wilson C, Passos JF, et al. Chronic inflammation induces telomere dysfunction and accelerates ageing in mice. Nat Commun. 2014 Jun 24;2:4172.
   PubMedGoogle Scholar
• Rodriguez-Brenes IA, Komarova NL, Wodarz D. The role of telomere shortening in carcinogenesis: a hybrid stochastic-deterministic approach. J Theor Biol. 2019 Jan 7;460:144–152.
   PubMed Web of Science ®Google Scholar
• Djojosubroto MW, Choi YS, Lee HW, et al. Telomeres and telomerase in aging, regeneration and cancer. Mol Cells. 2003 Apr 30;15(2):164–175.
   PubMed Web of Science ®Google Scholar
• Tanwar S, Rhodes F, Srivastava A, et al. Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C. World J Gastroenterol. 2020 Jan 14;26(2):109–133.
   PubMed Web of Science ®Google Scholar
• Wiemann SU, Satyanarayana A, Tsahuridu M, et al. Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J. 2002 Jul;16(9):935–942.
   PubMed Web of Science ®Google Scholar
• Nakajima T, Moriguchi M, Katagishi T, et al. Premature telomere shortening and impaired regenerative response in hepatocytes of individuals with NAFLD. Liver Int. 2006 Feb;26(1):23–31.
   PubMed Web of Science ®Google Scholar
• Barnard A, Moch A, Saab S. Relationship between telomere maintenance and liver disease. Gut Liver. 2019 Jan 15;13(1):11–15.
   PubMed Web of Science ®Google Scholar
• Satyanarayana A, Wiemann SU, Buer J, et al. Telomere shortening impairs organ regeneration by inhibiting cell cycle re-entry of a subpopulation of cells. EMBO J. 2003 Aug 1;22(15):4003–4013.
   PubMed Web of Science ®Google Scholar
• Greenberg RA. Telomeres, crisis and cancer. Curr Mol Med. 2005 Mar;5(2):213–218.
   PubMed Web of Science ®Google Scholar
• Plentz RR, Caselitz M, Bleck JS, et al. Hepatocellular telomere shortening correlates with chromosomal instability and the development of human hepatoma. Hepatology. 2004 Jul;40(1):80–86.
   PubMed Web of Science ®Google Scholar
• Aravinthan A, Scarpini C, Tachtatzis P, et al. Hepatocyte senescence predicts progression in non-alcohol-related fatty liver disease. J Hepatol. 2013 Mar;58(3):549–556.
   PubMed Web of Science ®Google Scholar
• Sekoguchi S, Nakajima T, Moriguchi M, et al. Role of cell-cycle turnover and oxidative stress in telomere shortening and cellular senescence in patients with chronic hepatitis C. J Gastroenterol Hepatol. 2007 Feb;22(2):182–190.
   PubMed Web of Science ®Google Scholar
• Takeda H, Takai A, Kumagai K, et al. Multiregional whole-genome sequencing of hepatocellular carcinoma with nodule-in-nodule appearance reveals stepwise cancer evolution. J Pathol. 2020 Dec;252(4):398–410.
   PubMed Web of Science ®Google Scholar
• Fredriksson NJ, Ny L, Nilsson JA, et al. Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types. Nat Genet. 2014 Dec;46(12):1258–1263.
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science. 2013 Mar 29;339(6127):1546–1558.
   PubMed Web of Science ®Google Scholar
• Xu X, Li Y, Bharath SR, et al. Structural basis for reactivating the mutant TERT promoter by cooperative binding of p52 and ETS1. Nat Commun. 2018 Aug 9;9(1):3183.
   PubMedGoogle Scholar
• Stern JL, Theodorescu D, Vogelstein B, et al. Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers. Genes Dev. 2015 Nov 1;29(21):2219–2224.
   PubMed Web of Science ®Google Scholar
• Akincilar SC, Khattar E, Boon PL, et al. Long-range chromatin interactions drive mutant TERT promoter activation. Cancer Discov. 2016 Nov;6(11):1276–1291.
   PubMed Web of Science ®Google Scholar
• Ningarhari M, Caruso S, Hirsch TZ, et al. Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target. J Hepatol. 2021 May;74(5):1155–1166.
   PubMed Web of Science ®Google Scholar
• Yuan X, Larsson C, Xu D. Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players. Oncogene. 2019 Aug;38(34):6172–6183.
   PubMed Web of Science ®Google Scholar
• Ramlee MK, Wang J, Toh WX, et al. Transcription regulation of the Human Telomerase Reverse Transcriptase (hTERT) gene. Genes (Basel). 2016 Aug 18;7(8):50.
   PubMed Web of Science ®Google Scholar
• Wu KJ, Grandori C, Amacker M, et al. Direct activation of TERT transcription by c-MYC. Nat Genet. 1999 Feb;21(2):220–224.
   PubMed Web of Science ®Google Scholar
• Oh ST, Kyo S, Laimins LA. Telomerase activation by human papillomavirus type 16 E6 protein: induction of human telomerase reverse transcriptase expression through Myc and GC-rich Sp1 binding sites. J Virol. 2001 Jun;75(12):5559–5566.
   PubMed Web of Science ®Google Scholar
• Gewin L, Myers H, Kiyono T, et al. Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 E6/E6-AP complex. Genes Dev. 2004 Sep 15;18(18):2269–2282.
   PubMed Web of Science ®Google Scholar
• Endoh T, Tsuji N, Asanuma K, et al. Survivin enhances telomerase activity via up-regulation of specificity protein 1- and c-Myc-mediated human telomerase reverse transcriptase gene transcription. Exp Cell Res. 2005 May 1;305(2):300–311.
   PubMed Web of Science ®Google Scholar
• Kyo S, Takakura M, Kanaya T, et al. Estrogen activates telomerase. Cancer Res. 1999 Dec 1;59(23):5917–5921.
   PubMed Web of Science ®Google Scholar
• Sheng WY, Chen YR, Wang TC. A major role of PKC theta and NFkappaB in the regulation of hTERT in human T lymphocytes. FEBS Lett. 2006 Dec 22;580(30):6819–6824.
   PubMed Web of Science ®Google Scholar
• Xu D, Dwyer J, Li H, et al. Ets2 maintains hTERT gene expression and breast cancer cell proliferation by interacting with c-Myc. J Biol Chem. 2008 Aug 29;283(35):23567–23580.
   PubMed Web of Science ®Google Scholar
• Kanzawa T, Komata T, Kyo S, et al. Down-regulation of telomerase activity in malignant glioma cells by p27KIP1. Int J Oncol. 2003 Dec;23(6):1703–1708.
   PubMed Web of Science ®Google Scholar
• Yoo YS, Park S, Gwak J, et al. Involvement of transcription repressor Snail in the regulation of human telomerase reverse transcriptase (hTERT) by transforming growth factor-beta. Biochem Biophys Res Commun. 2015 Sep 11;465(1):131–136.
   PubMed Web of Science ®Google Scholar
• Wang XH, Liu BR, Qu B, et al. Silencing STAT3 may inhibit cell growth through regulating signaling pathway, telomerase, cell cycle, apoptosis and angiogenesis in hepatocellular carcinoma: potential uses for gene therapy. Neoplasma. 2011;58(2):158–171.
   PubMed Web of Science ®Google Scholar
• Crowe DL, Nguyen DC, Tsang KJ, et al. E2F-1 represses transcription of the human telomerase reverse transcriptase gene. Nucleic Acids Res. 2001 Jul 1;29(13):2789–2794.
   PubMed Web of Science ®Google Scholar
• Lambert M, Jambon S, Depauw S, et al. Targeting transcription factors for cancer treatment. Molecules. 2018 Jun 19;23(6):1479.
   PubMed Web of Science ®Google Scholar
• Liu T, Yuan X, Xu D. Cancer-specific Telomerase Reverse Transcriptase (TERT) promoter mutations: biological and clinical implications. Genes (Basel). 2016 Jul 18;7(7):38.
   PubMed Web of Science ®Google Scholar
• Gabay M, Li Y, Felsher DW. MYC activation is a hallmark of cancer initiation and maintenance. Cold Spring Harb Perspect Med. 2014 Jun 2;4(6):a014241.
   PubMed Web of Science ®Google Scholar
• Llombart V, Mansour MR. Therapeutic targeting of “undruggable” MYC. EBioMedicine. 2022 Jan;75:103756.
   PubMed Web of Science ®Google Scholar
• Kaposi-Novak P, Libbrecht L, Woo HG, et al. Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res. 2009 Apr 1;69(7):2775–2782.
   PubMed Web of Science ®Google Scholar
• Wang J, Xie LY, Allan S, et al. Myc activates telomerase. Genes Dev. 1998 Jun 15;12(12):1769–1774.
   PubMed Web of Science ®Google Scholar
• Casillas MA, Brotherton SL, Andrews LG, et al. Induction of endogenous telomerase (hTERT) by c-Myc in WI-38 fibroblasts transformed with specific genetic elements. Gene. 2003 Oct 16;316:57–65.
   PubMed Web of Science ®Google Scholar
• Han H, Jain AD, Truica MI, et al. Small-molecule MYC inhibitors suppress tumor growth and enhance immunotherapy. Cancer Cell. 2019 Nov 11;36(5):483–497 e15.
   PubMed Web of Science ®Google Scholar
• Choi SH, Mahankali M, Lee SJ, et al. Targeted disruption of myc-max oncoprotein complex by a small molecule. ACS Chem Biol. 2017 Nov 17;12(11):2715–2719.
   PubMed Web of Science ®Google Scholar
• Jeong KC, Ahn KO, Yang CH. Small-molecule inhibitors of c-Myc transcriptional factor suppress proliferation and induce apoptosis of promyelocytic leukemia cell via cell cycle arrest. Mol Biosyst. 2010 Aug;6(8):1503–1509.
   PubMedGoogle Scholar
• Soucek L, Whitfield J, Martins CP, et al. Modelling Myc inhibition as a cancer therapy. Nature. 2008 Oct 2;455(7213):679–683.
   PubMed Web of Science ®Google Scholar
• Nusse R, Clevers H. Wnt/beta-catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017 Jun 1;169(6):985–999.
   PubMed Web of Science ®Google Scholar
• Hoffmeyer K, Raggioli A, Rudloff S, et al. Wnt/beta-catenin signaling regulates telomerase in stem cells and cancer cells. Science. 2012 Jun 22;336(6088):1549–1554.
   PubMed Web of Science ®Google Scholar
• Park JI, Venteicher AS, Hong JY, et al. Telomerase modulates Wnt signalling by association with target gene chromatin. Nature. 2009 Jul 2;460(7251):66–72.
   PubMed Web of Science ®Google Scholar
• Kotiyal S, Evason KJ. Exploring the interplay of telomerase reverse transcriptase and beta-catenin in hepatocellular carcinoma. Cancers (Basel). 2021 Aug 20;13(16):4202.
   PubMed Web of Science ®Google Scholar
• Hrdlickova R, Nehyba J, Bose HR Jr. Alternatively spliced telomerase reverse transcriptase variants lacking telomerase activity stimulate cell proliferation. Mol Cell Biol. 2012 Nov;32(21):4283–4296.
   PubMed Web of Science ®Google Scholar
• Yu F, Yu C, Li F, et al. Wnt/beta-catenin signaling in cancers and targeted therapies. Signal Transduct Target Ther. 2021 Aug 30;6(1):307.
   PubMed Web of Science ®Google Scholar
• Kim JY, Lee HY, Park KK, et al. CWP232228 targets liver cancer stem cells through Wnt/beta-catenin signaling: a novel therapeutic approach for liver cancer treatment. Oncotarget. 2016 Apr 12;7(15):20395–20409.
   PubMedGoogle Scholar
• Kim YJ, Yoo JE, Jeon Y, et al. Suppression of PROX1-mediated TERT expression in hepatitis B viral hepatocellular carcinoma. Int J Cancer. 2018 Dec 15;143(12):3155–3168.
   PubMed Web of Science ®Google Scholar
• Pedrioli DM, Karpanen T, Dabouras V, et al. miR-31 functions as a negative regulator of lymphatic vascular lineage-specific differentiation in vitro and vascular development in vivo. Mol Cell Biol. 2010 Jul;30(14):3620–3634.
   PubMed Web of Science ®Google Scholar
• Monsen RC, DeLeeuw L, Dean WL, et al. The hTERT core promoter forms three parallel G-quadruplexes. Nucleic Acids Res. 2020 Jun 4;48(10):5720–5734.
   PubMed Web of Science ®Google Scholar
• Palumbo SL, Ebbinghaus SW, Hurley LH. Formation of a unique end-to-end stacked pair of G-quadruplexes in the hTERT core promoter with implications for inhibition of telomerase by G-quadruplex-interactive ligands. J Am Chem Soc. 2009 Aug 12;131(31):10878–10891.
   PubMed Web of Science ®Google Scholar
• Chaires JB, Trent JO, Gray RD, et al. An improved model for the hTERT promoter quadruplex. PLoS One. 2014;9(12):e115580.
   PubMed Web of Science ®Google Scholar
• Song JH, Kang HJ, Luevano LA, et al. Small-molecule-targeting hairpin loop of hTERT promoter G-quadruplex induces cancer cell death. Cell Chem Biol. 2019 Aug 15;26(8):1110–1121 e4.
   PubMed Web of Science ®Google Scholar
• Kang HJ, Cui Y, Yin H, et al. A pharmacological chaperone molecule induces cancer cell death by restoring tertiary DNA structures in mutant hTERT promoters. J Am Chem Soc. 2016 Oct 19;138(41):13673–13692.
   PubMed Web of Science ®Google Scholar
• Zvereva MI, Zatsepin TS, Azhibek DM, et al. Oligonucleotide inhibitors of telomerase: prospects for anticancer therapy and diagnostics. Biochemistry (Mosc). 2015 Mar;80(3):251–259.
   PubMed Web of Science ®Google Scholar
• Du Q-Y, et al. Antitumor mechanism of antisense cantide targeting human telomerase reverse transcriptase. World J Gastroenterol. 2003 Sep;9(9):2030–2035.
   PubMed Web of Science ®Google Scholar
• Yang Y, Du, QY, Yang, BH, Lin, RX, Wang, SQ . Combined effects of Cantide and chemotherapeutic drugs on inhibition of tumor cells’ growth in vitro and in vivo. World J Gastroenterol. 2005 Apr 28;11(16):2491–2496.
   PubMed Web of Science ®Google Scholar
• Lin R-X, Tuo C-W, Lu Q-J, et al. Inhibition of tumor growth and metastasis with antisense oligonucleotides (Cantide) targeting hTERT in an in situ human hepatocellular carcinoma model. Acta Pharmacol Sin. 2005 Jun;26(6):762–768.
   PubMed Web of Science ®Google Scholar
• Seley-Radtke KL, Yates MK. The evolution of nucleoside analogue antivirals: a review for chemists and non-chemists. Part 1: early structural modifications to the nucleoside scaffold. Antiviral Res. 2018 Jun;154:66–86.
   PubMed Web of Science ®Google Scholar
• Sanford SL, Welfer GA, Freudenthal BD, et al. Mechanisms of telomerase inhibition by oxidized and therapeutic dNTPs. Nat Commun. 2020 Oct 20;11(1):5288.
   PubMed Web of Science ®Google Scholar
• Tornevik Y, Ullman B, Balzarini J, et al. Cytotoxicity of 3’-azido-3’-deoxythymidine correlates with 3’-azidothymidine-5’-monophosphate (AZTMP) levels, whereas anti-human immunodeficiency virus (HIV) activity correlates with 3’-azidothymidine-5’-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cells. Biochem Pharmacol. 1995 Mar 15;49(6):829–837.
   PubMed Web of Science ®Google Scholar
• Hajek M, Matulova N, Votruba I, et al. Inhibition of human telomerase by diphosphates of acyclic nucleoside phosphonates. Biochem Pharmacol. 2005 Sep 15;70(6):894–900.
   PubMed Web of Science ®Google Scholar
• Jeng KS, Sheen IS, Jeng WJ. Azidothymidine treatment of hepatocellular carcinoma in rats: an in vivo study of telomerase inhibition. Hepatogastroenterology. 2011 Nov-Dec;58(112):2091–2096.
   PubMedGoogle Scholar
• Fang JL, Beland FA. Long-term exposure to zidovudine delays cell cycle progression, induces apoptosis, and decreases telomerase activity in human hepatocytes. Toxicol Sci. 2009 Sep;111(1):120–130.
   PubMed Web of Science ®Google Scholar
• Sabokrouh A, Vaisi-Raygani A, Goodarzi MT, et al. Comparison between platinum-azidothymidine and azidothymidine effects on Bcl-2 and telomerase gene expression in rats with hepatocellular carcinoma. Avicenna J Med Biotechnol. 2015 Apr-Jun;7(2):50–56.
   PubMedGoogle Scholar
• Sekeroglu ZA, Sekeroglu V, Kucuk N. Effects of reverse transcriptase inhibitors on proliferation, apoptosis, and migration in breast carcinoma cells. Int J Toxicol. 2021 Jan-Feb;40(1):52–61.
   PubMed Web of Science ®Google Scholar
• Mender I, Gryaznov S, Dikmen ZG, et al. Induction of telomere dysfunction mediated by the telomerase substrate precursor 6-thio-2’-deoxyguanosine. Cancer Discov. 2015 Jan;5(1):82–95.
   PubMed Web of Science ®Google Scholar
• Herbert BS, Gellert GC, Hochreiter A, et al. Lipid modification of GRN163, an N3’–>P5’ thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene. 2005 Aug 4;24(33):5262–5268.
   PubMed Web of Science ®Google Scholar
• Djojosubroto MW, Chin AC, Go N, et al. Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma. Hepatology. 2005 Nov;42(5):1127–1136.
   PubMed Web of Science ®Google Scholar
• Pascolo E, Wenz C, Lingner J, et al. Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate. J Biol Chem. 2002 May 3;277(18):15566–15572.
   PubMed Web of Science ®Google Scholar
• Tahtouh R, Azzi AS, Alaaeddine N, et al. Telomerase inhibition decreases alpha-fetoprotein expression and secretion by hepatocellular carcinoma cell lines: in vitro and in vivo study. PLoS One. 2015;10(3):e0119512.
   PubMed Web of Science ®Google Scholar
• Hayakawa N, Nozawa K, Ogawa A, et al. Isothiazolone derivatives selectively inhibit telomerase from human and rat cancer cells in vitro. Biochemistry. 1999 Aug 31;38(35):11501–11507.
   PubMed Web of Science ®Google Scholar
• Tauchi T, Shin-ya K, Sashida G, et al. Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia. Oncogene. 2006 Sep 21;25(42):5719–5725.
   PubMed Web of Science ®Google Scholar
• Seimiya H, Nagasawa K, Shin-Ya K. Chemical targeting of G-quadruplexes in telomeres and beyond for molecular cancer therapeutics. J Antibiot (Tokyo). 2021 Oct;74(10):617–628.
   PubMed Web of Science ®Google Scholar
• Tauchi T, Shin-Ya K, Sashida G, et al. Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), against human leukemia cells: involvement of ATM-dependent DNA damage response pathways. Oncogene. 2003 Aug 14;22(34):5338–5347.
   PubMed Web of Science ®Google Scholar
• Jana J, Sengupta P, Mondal S, et al. Restriction of telomerase capping by short non-toxic peptides via arresting telomeric G-quadruplex [10.1039/C6RA28149D]. RSC Adv. 2017;7(34):20888–20899.
   Web of Science ®Google Scholar
• Hu MH, Lin XT, Liu B, et al. Dimeric aryl-substituted imidazoles may inhibit ALT cancer by targeting the multimeric G-quadruplex in telomere. Eur J Med Chem. 2020 Jan 15;186:111891.
   PubMed Web of Science ®Google Scholar
• Beevi SS, Mangamoori LN, Subathra M, et al. Hexane extract of Raphanus sativus L. roots inhibits cell proliferation and induces apoptosis in human cancer cells by modulating genes related to apoptotic pathway. Plant Foods Hum Nutr. 2010 Sep;65(3):200–209.
   PubMed Web of Science ®Google Scholar
• Lamy E, Mersch-Sundermann V. MTBITC mediates cell cycle arrest and apoptosis induction in human HepG2 cells despite its rapid degradation kinetics in the in vitro model. Environ Mol Mutagen. 2009 Apr;50(3):190–200.
   PubMed Web of Science ®Google Scholar
• Herz C, Hertrampf A, Zimmermann S, et al. The isothiocyanate erucin abrogates telomerase in hepatocellular carcinoma cells in vitro and in an orthotopic xenograft tumour model of HCC. J Cell Mol Med. 2014 Dec;18(12):2393–2403.
   PubMed Web of Science ®Google Scholar
• Naasani I, Seimiya H, Tsuruo T. Telomerase inhibition, telomere shortening, and senescence of cancer cells by tea catechins. Biochem Biophys Res Commun. 1998 Aug 19;249(2):391–396.
   PubMed Web of Science ®Google Scholar
• Seimiya H, Oh-hara T, Suzuki T, et al. Telomere shortening and growth inhibition of human cancer cells by novel synthetic telomerase inhibitors MST-312, MST-295, and MST-1991. Mol Cancer Ther. 2002 Jul;1(9):657–665.
   PubMed Web of Science ®Google Scholar
• Wang SJ, Yang PM. A Bioinformatics analysis identifies the telomerase inhibitor MST-312 for treating high-STMN1-Expressing hepatocellular carcinoma. J Pers Med. 2021 Apr 22;11(5):332.
   PubMed Web of Science ®Google Scholar
• Zhang R, Gao X, Zuo J, et al. STMN1 upregulation mediates hepatocellular carcinoma and hepatic stellate cell crosstalk to aggravate cancer by triggering the MET pathway. Cancer Sci. 2020 Feb;111(2):406–417.
   PubMed Web of Science ®Google Scholar
• Huo LF, Tang JW, Huang JJ, et al. Cancer immunotherapy targeting the telomerase reverse transcriptase. Cell Mol Immunol. 2006 Feb;3(1):1–11.
   PubMed Web of Science ®Google Scholar
• Zanetti M. A second chance for telomerase reverse transcriptase in anticancer immunotherapy. Nat Rev Clin Oncol. 2017 Feb;14(2):115–128.
   PubMed Web of Science ®Google Scholar
• Minev B, Hipp J, Firat H, et al. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4796–4801.
   PubMed Web of Science ®Google Scholar
• Mizukoshi E, Nakamoto Y, Marukawa Y, et al. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma. Hepatology. 2006 Jun;43(6):1284–1294.
   PubMed Web of Science ®Google Scholar
• Bernhardt SL, Gjertsen MK, Trachsel S, et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study. Br J Cancer. 2006 Dec 4;95(11):1474–1482.
   PubMed Web of Science ®Google Scholar
• Brunsvig PF, Aamdal S, Gjertsen MK, et al. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother. 2006 Dec;55(12):1553–1564.
   PubMed Web of Science ®Google Scholar
• Greten TF, Forner A, Korangy F, et al. A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer. 2010 May 17;10:209.
   PubMed Web of Science ®Google Scholar
• Kotsakis A, Vetsika EK, Christou S, et al. Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II study. Ann Oncol. 2012 Feb;23(2):442–449.
   PubMed Web of Science ®Google Scholar
• Laherty CD, Yang WM, Sun JM, et al. Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. Cell. 1997 May 2;89(3):349–356.
   PubMed Web of Science ®Google Scholar
• Xu D, Popov N, Hou M, et al. Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells. Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):3826–3831.
   PubMed Web of Science ®Google Scholar
• Hou M, Wang X, Popov N, et al. The histone deacetylase inhibitor trichostatin A derepresses the telomerase reverse transcriptase (hTERT) gene in human cells. Exp Cell Res. 2002 Mar 10;274(1):25–34.
   PubMed Web of Science ®Google Scholar
• Ning G, Li Y, Chen W, et al. Identification of new biomarker for prediction of hepatocellular carcinoma development in early-stage cirrhosis patients. J Oncol. 2021;2021:9949492.
   PubMed Web of Science ®Google Scholar
• Ding D, Chen LL, Zhai YZ, et al. Trichostatin A inhibits the activation of hepatic stellate cells by increasing C/EBP-alpha acetylation in vivo and in vitro. Sci Rep. 2018 Mar 13;8(1):4395.
   PubMedGoogle Scholar
• Bissell DM. Sex and hepatic fibrosis. Hepatology. 1999 Mar;29(3):988–989.
   PubMed Web of Science ®Google Scholar
• Xu JW, Gong J, Chang XM, et al. Estrogen reduces CCL4- induced liver fibrosis in rats. World J Gastroenterol. 2002 Oct;8(5):883–887.
   PubMed Web of Science ®Google Scholar
• Sato R, Maesawa C, Fujisawa K, et al. Prevention of critical telomere shortening by oestradiol in human normal hepatic cultured cells and carbon tetrachloride induced rat liver fibrosis. Gut. 2004 Jul;53(7):1001–1009.
   PubMed Web of Science ®Google Scholar
• Jacczak B, Rubis B, Toton E. Potential of naturally derived compounds in telomerase and telomere modulation in skin senescence and aging. Int J Mol Sci. 2021 Jun 15;22(12):6381.
   PubMed Web of Science ®Google Scholar
• Chau MN, El Touny LH, Jagadeesh S, et al. Physiologically achievable concentrations of genistein enhance telomerase activity in prostate cancer cells via the activation of STAT3. Carcinogenesis. 2007 Nov;28(11):2282–2290.
   PubMed Web of Science ®Google Scholar
• Akincilar SC, Chan CHT, Ng QF, et al. Non-canonical roles of canonical telomere binding proteins in cancers. Cell Mol Life Sci. 2021 May;78(9):4235–4257.
   PubMed Web of Science ®Google Scholar
• Rudolph KL, Chang S, Lee HW, et al. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell. 1999 Mar 5;96(5):701–712.
   PubMed Web of Science ®Google Scholar
• Masutomi K, Yu EY, Khurts S, et al. Telomerase maintains telomere structure in normal human cells. Cell. 2003 Jul 25;114(2):241–253.
   PubMed Web of Science ®Google Scholar
• Zheng Q, Huang J, Wang G. Mitochondria, telomeres and telomerase subunits. Front Cell Dev Biol. 2019;7:274.
   PubMed Web of Science ®Google Scholar
• Hengesbach M, Akiyama BM, Stone MD. Single-molecule analysis of telomerase structure and function. Curr Opin Chem Biol. 2011 Dec;15(6):845–852.
   PubMed Web of Science ®Google Scholar
• Shanmugam R, Ozturk MB, Low JL, et al. Genome-wide screens identify specific drivers of mutant hTERT promoters. Proc Natl Acad Sci U S A. 2022 Jan 18;119(3):e2105171119.
   PubMed Web of Science ®Google Scholar
• Guardigni V, Toschi A, Badia L, et al. Patients with HIV and cirrhosis: the risk for hepatocellular carcinoma after direct-acting antivirals for hepatitis C virus. Aids. 2021 Oct 1;35(12):1967–1972.
   PubMed Web of Science ®Google Scholar
• Liu R, Zhang T, Zhu G, et al. Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer. Nat Commun. 2018 Feb 8;9(1):579.
   PubMedGoogle Scholar
• Tan J, Liu R, Zhu G, et al. TERT promoter mutation determines apoptotic and therapeutic responses of BRAF-mutant cancers to BRAF and MEK inhibitors: achilles heel. Proc Natl Acad Sci U S A. 2020 Jul 7;117(27):15846–15851.
   PubMed Web of Science ®Google Scholar